MedTrace Logo

Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer

NCT06766643 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2025-01-09

No results posted yet for this study

Summary

A phase II clinical trial of stereotactic radiosurgery versus radiofrequency ablation in the treatment of inoperable primary liver cancer in specific sites

Conditions

  • Primary Liver Cancer

Interventions

PROCEDURE

Stereotactic Body Radiation Therapy (SBRT)

Stereotactic radiosurgery for liver lesions: with a total dose of 40\~50Gy/3\~5fraction;

PROCEDURE

Radiofrequency ablation therapy

Radiofrequency ablation therapy:1 complete radiofrequency ablation of liver lesions for liver lesions

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2025-01-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06766643 on ClinicalTrials.gov